Jill M Ferdinands1, David K Shay. 1. Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. jferdinands@cdc.gov
Abstract
BACKGROUND: Many influenza vaccine effectiveness estimates have been made using case-control methods. Although several forms of bias may distort estimates of vaccine effectiveness derived from case-control studies, there have been few attempts to quantify the magnitude of these biases. METHODS: We estimated the magnitude of potential biases in influenza vaccine effectiveness values derived from case-control studies from several factors, including bias from differential use of diagnostic testing based on influenza vaccine status, imperfect diagnostic test characteristics, and confounding. A decision tree model was used to simulate an influenza vaccine effectiveness case-control study in children. Using probability distributions, we varied the value of factors that influence vaccine effectiveness estimates, including diagnostic test characteristics, vaccine coverage, likelihood of receiving a diagnostic test for influenza, likelihood that a child hospitalized with acute respiratory infection had influenza, and others. Bias was measured as the difference between the effectiveness observed in the simulated case-control study and a true underlying effectiveness value. RESULTS AND CONCLUSIONS: We found an average difference between observed and true vaccine effectiveness of -11.9%. Observed vaccine effectiveness underestimated the true effectiveness in 88% of model iterations. Diagnostic test specificity exhibited the strongest association with observed vaccine effectiveness, followed by the likelihood of receiving a diagnostic test based on vaccination status and the likelihood that a child hospitalized with acute respiratory infection had influenza. Our findings suggest that the potential biases in case-control studies that we examined tend to result in underestimates of true influenza vaccine effects.
BACKGROUND: Many influenza vaccine effectiveness estimates have been made using case-control methods. Although several forms of bias may distort estimates of vaccine effectiveness derived from case-control studies, there have been few attempts to quantify the magnitude of these biases. METHODS: We estimated the magnitude of potential biases in influenza vaccine effectiveness values derived from case-control studies from several factors, including bias from differential use of diagnostic testing based on influenza vaccine status, imperfect diagnostic test characteristics, and confounding. A decision tree model was used to simulate an influenza vaccine effectiveness case-control study in children. Using probability distributions, we varied the value of factors that influence vaccine effectiveness estimates, including diagnostic test characteristics, vaccine coverage, likelihood of receiving a diagnostic test for influenza, likelihood that a child hospitalized with acute respiratory infection had influenza, and others. Bias was measured as the difference between the effectiveness observed in the simulated case-control study and a true underlying effectiveness value. RESULTS AND CONCLUSIONS: We found an average difference between observed and true vaccine effectiveness of -11.9%. Observed vaccine effectiveness underestimated the true effectiveness in 88% of model iterations. Diagnostic test specificity exhibited the strongest association with observed vaccine effectiveness, followed by the likelihood of receiving a diagnostic test based on vaccination status and the likelihood that a child hospitalized with acute respiratory infection had influenza. Our findings suggest that the potential biases in case-control studies that we examined tend to result in underestimates of true influenza vaccine effects.
Authors: Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto Journal: Clin Infect Dis Date: 2013-11-13 Impact factor: 9.079
Authors: Kate Russell; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Brendan Flannery Journal: Vaccine Date: 2018-02-28 Impact factor: 3.641
Authors: Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Benjamin J Cowling; Mark G Thompson; David K Shay; Arnold S Monto Journal: Clin Infect Dis Date: 2013-02-14 Impact factor: 9.079
Authors: Peng-Jun Lu; Alissa O'Halloran; Leah Bryan; Erin D Kennedy; Helen Ding; Samuel B Graitcer; Tammy A Santibanez; Ankita Meghani; James A Singleton Journal: Am J Infect Control Date: 2014-05-03 Impact factor: 2.918
Authors: Michael L Jackson; Jessie R Chung; Lisa A Jackson; C Hallie Phillips; Joyce Benoit; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard Zimmerman; Mary P Nowalk; Alicia M Fry; Brendan Flannery Journal: N Engl J Med Date: 2017-08-10 Impact factor: 91.245